Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
NEW YORK, Sept. 28, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased American Renal Associates Holdings, Inc. (NYSE:ARA) (“ARA” or “the Company”) securities (1) pursuant and/or traceable to the Initial Public Offering on or about April 21, 2016; and/or (2) between April 21, 2016 and August 18, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/american-renal-associates. There is no cost or obligation to you.
According to the complaint, during the Class Period, ARA made false and/or misleading statements and/or failed to disclose that: (1) ARA was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for ARA’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, ARA’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you suffered a loss in ARA you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/american-renal-associates.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
